Observational studies have found that elevated glial fibrillary acidic protein (GFAP) and triggering receptor expressed on myeloid cell 2 (TREM2) in blood and CSF can serve as biomarker events for the diagnosis of early AD [67, 68]. This evidence concerns the gene TREM2 and Alzheimer disease.